Literature DB >> 19292831

Blockade of K(ATP) channels reduces endothelial hyperpolarization and leukocyte recruitment upon reperfusion after hypoxia.

M Figura1, L Chilton, A Liacini, M Maric Viskovic, V Phan, D Knight, T M Millar, K Patel, P Kubes, W R Giles, L A Tibbles.   

Abstract

Ischemia/reperfusion injury in renal transplantation leads to slow or initial nonfunction, and predisposes to acute and chronic rejection. In fact, severe ischemia reperfusion injury can significantly reduce graft survival, even with modern immunosuppressive agents. One of the mechanisms by which ischemia/reperfusion causes injury is activation of endothelial cells resulting in inflammation. Although several therapies can be used to prevent leukocyte recruitment to ischemic vessels (e.g. antiadhesion molecule antibodies), there have been no clinical treatments reported that can prevent initial immediate neutrophil recruitment upon reperfusion. Using intravital microscopy, we describe abrogation of immediate neutrophil recruitment to ischemic microvessels by the K(ATP) antagonist glibenclamide (Glyburide). Further, we show that glibenclamide can reduce leukocyte recruitment in vitro under physiologic flow conditions. ATP-regulated potassium channels (K(ATP)) are important in the control of cell membrane polarization. Here we describe profound hyperpolarization of endothelial cells during hypoxia, and the reduction of this hyperpolarization using glibenclamide. These findings suggest that control of endothelial membrane potential during ischemia may be an important therapeutic tool in avoiding ischemia/reperfusion injury, and therefore, enhancing transplant long-term function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19292831     DOI: 10.1111/j.1600-6143.2009.02553.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  9 in total

1.  The antidiabetic agent glibenclamide protects airway hyperresponsiveness and inflammation in mice.

Authors:  Wei Cui; Shufang Zhang; Zhijian Cai; Xinlei Hu; Ruifeng Zhang; Yong Wang; Na Li; Zhihua Chen; Gensheng Zhang
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

Review 2.  Hydrogen sulphide and angiogenesis: mechanisms and applications.

Authors:  Csaba Szabó; Andreas Papapetropoulos
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Comparative effects of glibenclamide and riluzole in a rat model of severe cervical spinal cord injury.

Authors:  J Marc Simard; Orest Tsymbalyuk; Kaspar Keledjian; Alexander Ivanov; Svetlana Ivanova; Volodymyr Gerzanich
Journal:  Exp Neurol       Date:  2011-12-08       Impact factor: 5.330

4.  Platelet mitochondrial cytochrome c oxidase subunit I variants with benzene poisoning.

Authors:  Dianpeng Wang; Xiangli Yang; Yanfang Zhang; Dafeng Lin; Paimao Li; Zhiming Zhang; Xianqing Huang; Dayong Gu; Jacky Fong-Chuen Loo
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 5.  Glibenclamide in cerebral ischemia and stroke.

Authors:  J Marc Simard; Kevin N Sheth; W Taylor Kimberly; Barney J Stern; Gregory J del Zoppo; Sven Jacobson; Volodymyr Gerzanich
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

Review 6.  Sulfonylurea receptor 1 in central nervous system injury: a focused review.

Authors:  J Marc Simard; S Kyoon Woo; Gary T Schwartzbauer; Volodymyr Gerzanich
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-20       Impact factor: 6.200

7.  ATP-sensitive potassium channels alleviate postoperative pain through JNK-dependent MCP-1 expression in spinal cord.

Authors:  Xiang Zhu; Jinqian Liu; Yongjing Gao; Su Cao; Shiren Shen
Journal:  Int J Mol Med       Date:  2015-03-17       Impact factor: 4.101

8.  Effect of soluble sulfide on the activity of luminescent bacteria.

Authors:  Ying Shao; Ling-Ling Wu; Hong-Wen Gao; Feng Wang
Journal:  Molecules       Date:  2012-05-21       Impact factor: 4.411

Review 9.  Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: evidence to date.

Authors:  Zachary A King; Kevin N Sheth; W Taylor Kimberly; J Marc Simard
Journal:  Drug Des Devel Ther       Date:  2018-08-15       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.